Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Hyperhidrosis

In brief

This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.

Key facts

Study ID

NCT02193139

Run by

Watson Pharmaceuticals

People needed

195

Starts

2013-12-01

Expected to finish

2014-06-01

Last updated by the study team

2015-08-06

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Healthy volunteers with primary axillary hyperhidrosis
• Poor quality of life rating on the Hyperhidrosis Disease Severity Scale (score of 3 or 4)
• Has a baseline gravimetric measurement of spontaneous resting sweat production of ≥100 mg/10 min at room at room temperature in at least one axilla
• Meets at least two of the following criteria (self-reported):
• sweating is bilateral and symmetrical
• excessive sweating impairs daily activities
• subject experiences at least one sweating episode per week
• excessive sweating onset was earlier than age 25 years
• has a positive family history for excessive sweating
• cessation of sweating during sleep

Where it is running

• Watson Clinical Site — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.